Your browser doesn't support javascript.
loading
Copy number signatures and mutational processes in ovarian carcinoma.
Macintyre, Geoff; Goranova, Teodora E; De Silva, Dilrini; Ennis, Darren; Piskorz, Anna M; Eldridge, Matthew; Sie, Daoud; Lewsley, Liz-Anne; Hanif, Aishah; Wilson, Cheryl; Dowson, Suzanne; Glasspool, Rosalind M; Lockley, Michelle; Brockbank, Elly; Montes, Ana; Walther, Axel; Sundar, Sudha; Edmondson, Richard; Hall, Geoff D; Clamp, Andrew; Gourley, Charlie; Hall, Marcia; Fotopoulou, Christina; Gabra, Hani; Paul, James; Supernat, Anna; Millan, David; Hoyle, Aoisha; Bryson, Gareth; Nourse, Craig; Mincarelli, Laura; Sanchez, Luis Navarro; Ylstra, Bauke; Jimenez-Linan, Mercedes; Moore, Luiza; Hofmann, Oliver; Markowetz, Florian; McNeish, Iain A; Brenton, James D.
Afiliação
  • Macintyre G; Cancer Research UK Cambridge Institute, Cambridge, UK.
  • Goranova TE; Cancer Research UK Cambridge Institute, Cambridge, UK.
  • De Silva D; Cancer Research UK Cambridge Institute, Cambridge, UK.
  • Ennis D; Institute of Cancer Sciences, University of Glasgow, Glasgow, UK.
  • Piskorz AM; Cancer Research UK Cambridge Institute, Cambridge, UK.
  • Eldridge M; Cancer Research UK Cambridge Institute, Cambridge, UK.
  • Sie D; VU University Medical Center, Amsterdam, the Netherlands.
  • Lewsley LA; Cancer Research UK Clinical Trials Unit, Institute of Cancer Sciences, University of Glasgow, Glasgow, UK.
  • Hanif A; Cancer Research UK Clinical Trials Unit, Institute of Cancer Sciences, University of Glasgow, Glasgow, UK.
  • Wilson C; Cancer Research UK Clinical Trials Unit, Institute of Cancer Sciences, University of Glasgow, Glasgow, UK.
  • Dowson S; Institute of Cancer Sciences, University of Glasgow, Glasgow, UK.
  • Glasspool RM; Beatson West of Scotland Cancer Centre, Glasgow, UK.
  • Lockley M; Barts Cancer Institute, Queen Mary University of London, London, UK.
  • Brockbank E; University College London Hospital, London, UK.
  • Montes A; Barts Health NHS Trust, London, UK.
  • Walther A; Guy's Hospital, London, UK.
  • Sundar S; Bristol Cancer Institute, Bristol, UK.
  • Edmondson R; City Hospital, Birmingham, UK.
  • Hall GD; Division of Cancer Sciences, Faculty of Biology, Medicine and Health, University of Manchester, St Mary's Hospital, Manchester, UK.
  • Clamp A; Department of Obstetrics and Gynaecology, Manchester Academic Health Science Centre, St Mary's Hospital, Central Manchester NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK.
  • Gourley C; St James's Institute of Oncology, Leeds, UK.
  • Hall M; The Christie Hospital, Manchester, UK.
  • Fotopoulou C; Nicola Murray Centre for Ovarian Cancer Research, MRC IGMM, University of Edinburgh, Edinburgh, UK.
  • Gabra H; Mount Vernon Cancer Centre, Northwood, UK.
  • Paul J; Division of Cancer and Ovarian Cancer Action Research Centre, Department of Surgery and Cancer, Imperial College, London, UK.
  • Supernat A; Division of Cancer and Ovarian Cancer Action Research Centre, Department of Surgery and Cancer, Imperial College, London, UK.
  • Millan D; Early Clinical Development, IMED Biotech Unit, AstraZeneca, Cambridge, UK.
  • Hoyle A; Cancer Research UK Clinical Trials Unit, Institute of Cancer Sciences, University of Glasgow, Glasgow, UK.
  • Bryson G; Cancer Research UK Cambridge Institute, Cambridge, UK.
  • Nourse C; Department of Pathology, Queen Elizabeth University Hospital, Glasgow, UK.
  • Mincarelli L; Department of Pathology, Queen Elizabeth University Hospital, Glasgow, UK.
  • Sanchez LN; Department of Pathology, Queen Elizabeth University Hospital, Glasgow, UK.
  • Ylstra B; Institute of Cancer Sciences, University of Glasgow, Glasgow, UK.
  • Jimenez-Linan M; Institute of Cancer Sciences, University of Glasgow, Glasgow, UK.
  • Moore L; Institute of Cancer Sciences, University of Glasgow, Glasgow, UK.
  • Hofmann O; VU University Medical Center, Amsterdam, the Netherlands.
  • Markowetz F; Addenbrooke's Hospital, Cambridge, UK.
  • McNeish IA; Addenbrooke's Hospital, Cambridge, UK.
  • Brenton JD; Institute of Cancer Sciences, University of Glasgow, Glasgow, UK.
Nat Genet ; 50(9): 1262-1270, 2018 09.
Article em En | MEDLINE | ID: mdl-30104763
ABSTRACT
The genomic complexity of profound copy number aberrations has prevented effective molecular stratification of ovarian cancers. Here, to decode this complexity, we derived copy number signatures from shallow whole-genome sequencing of 117 high-grade serous ovarian cancer (HGSOC) cases, which were validated on 527 independent cases. We show that HGSOC comprises a continuum of genomes shaped by multiple mutational processes that result in known patterns of genomic aberration. Copy number signature exposures at diagnosis predict both overall survival and the probability of platinum-resistant relapse. Measurement of signature exposures provides a rational framework to choose combination treatments that target multiple mutational processes.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Ovarianas / Variações do Número de Cópias de DNA / Mutação Limite: Adult / Aged / Aged80 / Female / Humans / Middle aged Idioma: En Revista: Nat Genet Assunto da revista: GENETICA MEDICA Ano de publicação: 2018 Tipo de documento: Article País de afiliação: Reino Unido

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Ovarianas / Variações do Número de Cópias de DNA / Mutação Limite: Adult / Aged / Aged80 / Female / Humans / Middle aged Idioma: En Revista: Nat Genet Assunto da revista: GENETICA MEDICA Ano de publicação: 2018 Tipo de documento: Article País de afiliação: Reino Unido